Vir Biotechnology, Inc.
NASDAQ:VIRBiotechnology
Healthcare
$9.15 -2.63%
-$0.25 today
- Market cap
- $1.57B
- Beta
- 1.64
- P/E (TTM)
- -3.0
- EPS (TTM)
- -$3.00
52W Low $4.16High $11.66
Volume 2.15M
Average 1.76M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$391.78M
FY 2025 · Annual
Investing Cash Flow
$310.37M
FY 2025 · Annual
-37.8% YoYFinancing Cash Flow
$3.79M
FY 2025 · Annual
-13.7% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 528.58M | 515.84M | (615.06M) | (521.96M) | (437.99M) |
| Depreciation & Amortization | 5.81M | 6.78M | 19.45M | 14.56M | 21.15M |
| Deferred Income Tax | 15.19M | (15.19M) | (1.06M) | (2.95M) | 0 |
| Stock-Based Compensation | 83.78M | 102.08M | 0 | 78.46M | 49.07M |
| Change in Working Capital | (628.39M) | 665.37M | (304.59M) | (84.01M) | (22.45M) |
| Accounts Receivables | (773.08M) | 770.04M | (565K) | (6.51M) | 0 |
| Inventory | 52.82M | 0 | 0 | 0 | 0 |
| Accounts Payables | (171K) | 797K | 732K | (988K) | 5M |
| Other Working Capital | 92.04M | (105.47M) | (304.76M) | (76.51M) | (27.44M) |
| Other Non-Cash Items | (52.56M) | 388.37M | 122.48M | 69.55M | (1.57M) |
| Operating Cash Flow | (47.59M) | 1.66B | (778.79M) | (446.35M) | (391.78M) |
| Capital Expenditures | (21.82M) | (68.01M) | (21.57M) | (7.3M) | (4.83M) |
| Acquisitions (Net) | 140.81M | 0 | 100K | 3.37M | 253K |
| Purchases of Investments | (420.24M) | (1.48B) | (2.02B) | (1.24B) | (886.33M) |
| Sales of Investments | 301.24M | 351.51M | 2.2B | 1.74B | 1.2B |
| Other Investing Activities | (140.81M) | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (140.81M) | (1.19B) | 164.73M | 499.37M | 310.37M |
| Debt Repayment | (259K) | (260K) | (287K) | (165K) | (361K) |
| Common Stock Issued | 85.21M | 28.46M | 7.77M | 4.55M | 4.15M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 15.38M | 6.56M | (100K) | 0 | 0 |
| Financing Cash Flow | 100.33M | 34.76M | 7.38M | 4.39M | 3.79M |
| Effect of Forex Changes | 0 | 0 | 208K | 0 | 0 |
| Net Change in Cash | (88.07M) | 504.55M | (606.47M) | 57.4M | (77.63M) |
| Free Cash Flow | (69.41M) | 1.6B | (800.36M) | (453.65M) | (396.61M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$438.0M
+ D&A$21.2M
+ Stock-Based Comp$49.1M
+ Deferred Tax$0
- Working Capital-$22.4M
- Other Non-Cash-$1.6M
= Operating Cash Flow-$391.8M
- Capex-$4.8M
= Free Cash Flow-$396.6M
Analysis
FY2025 free cash flow is -$396.6M. FCF conversion is 90.6% of net income. Operating cash flow was -$391.8M, with capex of -$4.8M. The largest bridge item is Stock-Based Comp at $49.1M.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 424B5 | 424B5 filing | Nov 12, 2026 | |
| S-3ASR | S-3ASR filing | Nov 12, 2026 | |
| SC 13G | SC 13G filing | Nov 10, 2026 | |
| 8-K | Current report | Nov 9, 2026 | |
| SC 13D/A | SC 13D/A filing | Nov 6, 2026 |
Does VIR generate free cash flow?
Vir Biotechnology, Inc. (VIR) generated -$396.61M of free cash flow in fiscal 2025.
How much operating cash flow does VIR produce?
Operating cash flow was -$391.78M, before capital expenditures of $4.83M.
Continue the stock analysis
Jump to another research area for this company.